HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $61 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $61 price target.
May 22, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Mirum Pharmaceuticals and maintained a $61 price target.
The reiteration of the Buy rating and maintenance of the $61 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Mirum Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100